Bayer AG (BAYRY)
15.33
-0.19
(-1.22%)
USD |
OTCM |
Nov 06, 16:00
Bayer Enterprise Value : 102.60B for Nov. 6, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 06, 2026 | 102.60B |
| November 05, 2026 | 103.35B |
| November 04, 2026 | 102.17B |
| November 03, 2026 | 98.99B |
| November 02, 2026 | 97.18B |
| October 30, 2026 | 97.34B |
| October 29, 2026 | 94.90B |
| October 28, 2026 | 92.66B |
| October 27, 2026 | 92.66B |
| October 26, 2026 | 92.23B |
| October 23, 2026 | 90.70B |
| October 22, 2026 | 91.09B |
| October 21, 2026 | 91.44B |
| October 20, 2026 | 90.34B |
| October 19, 2026 | 89.99B |
| October 16, 2026 | 91.37B |
| October 15, 2026 | 91.17B |
| October 14, 2026 | 91.64B |
| October 13, 2026 | 90.82B |
| October 12, 2026 | 90.34B |
| October 09, 2026 | 90.46B |
| October 08, 2026 | 89.79B |
| October 07, 2026 | 90.54B |
| October 06, 2026 | 91.17B |
| October 05, 2026 | 91.05B |
| Date | Value |
|---|---|
| October 02, 2026 | 92.03B |
| October 01, 2026 | 92.39B |
| September 30, 2026 | 95.41B |
| September 29, 2026 | 93.76B |
| September 28, 2026 | 96.00B |
| September 25, 2026 | 95.45B |
| September 24, 2026 | 94.66B |
| September 23, 2026 | 94.51B |
| September 22, 2026 | 94.90B |
| September 21, 2026 | 94.35B |
| September 18, 2026 | 93.25B |
| September 17, 2026 | 94.70B |
| September 16, 2026 | 94.39B |
| September 15, 2026 | 94.33B |
| September 14, 2026 | 95.25B |
| September 11, 2026 | 94.00B |
| September 10, 2026 | 94.47B |
| September 09, 2026 | 95.41B |
| September 08, 2026 | 95.45B |
| September 04, 2026 | 94.94B |
| September 03, 2026 | 95.55B |
| September 02, 2026 | 95.06B |
| September 01, 2026 | 94.66B |
| August 31, 2026 | 95.17B |
| August 28, 2026 | 94.27B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Merck KGaA | 33.40B |
| Breakthrough Chemistry, Inc. | 0.1194M |
| Cardiac Biotech Solutions, Inc. | 6.406M |
| Fresenius SE & Co. KGaA | 44.49B |
| Carl Zeiss Meditec AG | 3.491B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -760.49M |
| Revenue (Quarterly) | 11.57B |
| Total Expenses (Quarterly) | 12.34B |
| EPS Diluted (Quarterly) | -0.1967 |
| Gross Profit Margin (Quarterly) | 54.23% |
| Profit Margin (Quarterly) | -6.58% |
| Earnings Yield | -2.75% |
| Operating Earnings Yield | 11.13% |
| Normalized Earnings Yield | 2.943 |